Impact of expanded antiretroviral use on incidence and prevalence of tuberculosis in children with HIV in Kenya

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 10, 2013, Pages 1291-1297

  Abuogi, Lisa L ^a,b   Mwachari, C ^b,c   Leslie, H H ^a   Shade, S B ^a   Otieno, J ^d   Yienya, N ^b   Sanguli, L ^b,c   Amukoye, E ^c   Cohen, C R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Family AIDS Care and Education Services   (Kenya)

^c Centre for Respiratory Disease Research   (Kenya)

^d New Nyanza Provincial General Hospital   (Kenya)

Author keywords

Epidemiology; Hiv 1; Pediatrics; Sub saharan africa; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADOLESCENT; ARTICLE; CD4+ T LYMPHOCYTE; CHILD; COHORT ANALYSIS; COUGHING; DRUG USE; FAILURE TO THRIVE; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFANT; INFECTION PREVENTION; INFECTION RISK; KENYA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; WEIGHT REDUCTION;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; INFANT; KENYA; LOGISTIC MODELS; MALE; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TUBERCULOSIS;

EID: 84884598352     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0740     Document Type: Article

References (27)

1. United Nations International Children's Emergency Fund. Children and AIDS. 5th Stocktaking Report 2010. Geneva, Switzerland: UNICEF, 2010.
2. Elenga N, Kouakoussui K A, Bonard D, et al. Diagnosed tuberculosis during the follow-up of a cohort of human immunodefi ciency virus-infected children in Abidjan, Cote d'Ivoire: ANRS 1278 study. Pediatr Infect Dis J 2005; 24: 1077-1082.
3. Berggren Palme I, Gudetta B, Degefu H, Muhe L, Bruchfeld J, Giesecke J. A controlled estimate of the risk of HIV infection in Ethiopian children with tuberculosis. Epidemiol Infect 2001; 127: 517-525.
4. Walters E, Cotton M F, Rabie H, Schaaf H S, Walters L O, Marais B J. Clinical presentation and outcome of tuberculosis in human immunodefi ciency virus infected children on antiretroviral therapy. BMC Pediatr 2008; 8: 1.
5. Newton S M, Brent A J, Anderson S, Whittaker E, Kampmann B. Paediatric tuberculosis. Lancet Infect Dis 2008; 8: 498- 510.
6. Braitstein P, Nyandiko W, Vreeman R, et al. The clinical burden of tuberculosis among human immunodefi ciency virus-infected children in Western Kenya and the impact of combination antiretroviral treatment. Pediatr Infect Dis J 2009; 28: 626-632.
7. Pearce E C, Woodward J F, Nyandiko W M, Vreeman R C, Ayaya S O. A systematic review of clinical diagnostic systems used in the diagnosis of tuberculosis in children. AIDS Res Treat 2012; 2012: 401896.
8. Coovadia H M, Jeena P, Wilkinson D. Childhood human immunodefi ciency virus and tuberculosis co-infections: reconciling confl icting data. Int J Tuberc Lung Dis 1998; 2: 844-851.
9. Verhagen L M, Warris A, van Soolingen D, de Groot R, Hermans P W. Human immunodefi ciency virus and tuberculosis coinfection in children: challenges in diagnosis and treatment. Pediatr Infect Dis J 2010; 29: e63-70.
10. Edmonds A, Lusiama J, Napravnik S, Kitetele F, Van Rie A, Behets F. Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children. Int J Epidemiol 2009; 38: 1612- 1621.
11. Bakeera-Kitaka S, Conesa-Botella A, Dhabangi A, et al. Tuberculosis in human immunodefi ciency virus infected Ugandan children starting on antiretroviral therapy. Int J Tuberc Lung Dis 2011; 15: 1082-1086.
12. Martinson N A, Moultrie H, van Niekerk R, et al. HAART and risk of tuberculosis in HIV-infected South African children: A multi-site retrospective cohort. Int J Tuberc Lung Dis 2009; 13: 862-867.
13. Frigati L J, Kranzer K, Cotton M F, Schaaf H S, Lombard C J, Zar H J. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting. Thorax 2011; 66: 496-501.
14. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. 2010 Revision. Geneva, Switzerland: WHO, 2010.
15. Ministry of Medical Services Kenya. Change in paediatric ART recommendations-early initiation of ART in infants. Nairobi, Kenya: Ministry of Health, 2008.
16. Ministry of Public Health and Sanitation Kenya. Annual report 2010. Nairobi, Kenya: Division of Leprosy TB and Lung Disease, Ministry of Health, 2010.
17. National Leprosy and Tuberculosis Programme Kenya. NLTP guidelines on management of leprosy and tuberculosis. Nairobi, Kenya: Ministry of Health, 2008.
18. Edwards K. The diagnosis of childhood tuberculosis. PNG Med J 1987; 30: 169-178.
19. World Health Organization. TB-HIV A clinical manual. WHO/HTM/TB/2004.329. Geneva, Switzerland: WHO, 2004.
20. Hesseling A C, Schaaf H S, Gie R P, Starke J R, Beyers N. A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis. Int J Tuberc Lung Dis 2002; 6: 1038-1045.
21. Graham S M, Ahmed T, Amanullah F, et al. Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis 2012; 205 (Suppl 2): S199-S208.
22. World Health Organization. WHO child growth standards. Geneva, Switzerland: WHO, 2011.
23. World Health Organization. WHO case defi nitions for HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva, Switzerland: WHO, 2007.
24. Hung C C, Chen M Y, Hsiao C F, et al. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS 2003; 17: 2615-2622.
25. World Health Organization. Guidelines for intensifi ed tuberculosis case-fi nding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland: WHO, 2011.
26. Zar H J, Cotton M F, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 2007; 334: 136.
27. Madhi S A, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med 2011; 365: 21-31.